Figure 2.

Percentage of patients who achieved undetectable PSA during the treatment phase increased with each component of multimodal therapy. Response to treatment was assessed with serum PSA measurements, and the frequency of patients who achieved undetectable PSA after ADT alone, ADT + surgery, and ADT + surgery + radiation is shown. ADT, androgen deprivation therapy; M1a, extrapelvic nodal disease; M1b, bone metastasis; PSA, prostate-specific antigen.